Exhibitor Product Theaters
In-Person Exhibitor Product Theater
Open to all in-person ACG 2024 attendees. These presentations provide additional educational opportunities for attendees. No CME is provided for Theater presentations.
The Exhibitor Product Theater is located in Booth 1171 in the Exhibit Hall (Level 200).
Sunday, October 27
Exploring Treatment Options for UC
Miguel D. Regueiro, MD, FACG
5:15 pm – 6:00 pm
Join Dr. Miguel Regueiro on Sunday, October 27th at 5:15 PM in a presentation sponsored by AbbVie. Dr. Regueiro will explore endoscopic outcomes and remission in a first-line treatment for adults with moderately to severely active ulcerative colitis.
This program is sponsored by AbbVie.
Adding on Second-Line Therapy to Help Change the Course of Treatment in PBC
Steven Flamm, MD, FACG
6:15 pm – 7:00 pm
Join us for an informative presentation that discusses liver health and taking treatment for Primary Biliary Cholangitis (PBC) a step further. Learn about an approved therapy for patients with PBC.
This program is sponsored by Intercept Pharmaceuticals, Inc.
Monday, October 28
Optimizing Management of Constipation and Abdominal Symptoms in Adult IBS-C Patients. Time to have a deeper conversation with your adult patients with IBS-C
Brooks D. Cash, MD, FACG
10:30 am – 11:15 am
Constipation and abdominal symptoms are the hallmark symptoms of IBS-C, a chronic and burdensome condition. Come to a clinical review to learn more about management of IBS-C in adults.
This program is sponsored by AbbVie.
All About ENTYVIO® (vedolizumab) Subcutaneous Pen
Asher Kornbluth, MD
11:30 am – 12:00 noon
This program is sponsored by Takeda Pharmaceuticals U.S.A., Inc.
Discover a Treatment Option that is Available for Patients with NASH with Liver Fibrosis
Kimberly A. Brown, MD and Anthony Martinez, MD
12:15 pm – 12:45 pm
Please join us for an engaging and highly anticipated educational presentation focusing on this treatment option for patients with NASH, including the clinical data.
This program is sponsored by Madrigal Pharmaceuticals, Inc.
Head-to-Head in CD
Remo Panaccione, MD
1:00 pm – 1:30 pm
Join Dr. Remo Panaccione on Monday, October 28th at 1:00 PM EST for a presentation sponsored by AbbVie. Dr. Panaccione will review the results of 2 biologics in a head-to-head clinical trial evaluating moderate to severe Crohn’s disease.
This program is sponsored by AbbVie.
Spotlight on Eosinophilic Esophagitis: Perspectives on defining control and optimizing disease management
Joshua B. Wechsler, MD, MSCI
1:45 pm – 2:15 pm
Join us as we explore how and why eosinophilic esophagitis management strategies should evolve with our increased understanding of disease pathogenesis.
This program is sponsored by Sanofi and Regeneron.
Integrating a Different Mechanism of Action, A Different Class of Therapy Into the Treatment of Adults with IBS-C
Darren M. Brenner, MD, FACG
2:30 pm – 3:00 pm
This program is sponsored by Ardelyx.
Introducing A First-in-Class Acid Suppressant for Adults With Erosive and Non-Erosive GERD
Brooks D. Cash, MD, FACG
3:45 pm – 4:30 pm
Objectives:
Join Brooks D. Cash, MD, FACG for an engaging session on therapeutic options for the treatment of GERD (gastroesophageal reflux disease) in adults.
This program is sponsored by Phathom Pharmaceuticals.
Tuesday, October 29
What's Next for Patients with Moderately to Severely Active UC
Miguel D. Regueiro, MD, FACG and Jessica R. Allegretti, MD, MPH, FACG
10:35 am – 11:30 am
Discuss the role of inflammation in UC, review relevant clinical data and the importance of various clinical outcomes.
This program is sponsored by Johnson and Johnson.
Learn About Omvoh: Some Discoveries Are Too Urgent to Ignore
Bincy P. Abraham, MD, MS, FACG and Kim Kearns, APRN
12:30 pm – 1:00 pm
This presentation includes an overview of disease symptoms/burden and the efficacy and safety data from relevant clinical studies. The facilitator will provide clinical insights and be available for a live Q&A session following the presentation.
This program is sponsored by Lilly.
Eosinophilic Esophagitis: A Treatment Option for Your Appropriate Patients
Nirmala Gonsalves, MD, FACG
1:15 pm – 1:45 pm
Join us to discover how inhibition of 2 key cytokines can impact your patient’s disease. An expert will walk through the efficacy and safety of a treatment option, leaving you with a better understanding of the effect of dual inhibition in EoE.
This program is sponsored by Sanofi and Regeneron.
Finding high-risk progressors from nondysplastic Barrett's esophagus patients
Phillip Woodworth, MD and Jay N. Yepuri, MD, MS, FACG
2:00 pm – 2:30 pm
Recent AGA guidelines recognized a subset of patients with NDBE that progress at a rate similar to higher grades of dysplasia. Clinical case discussions of how to identify high risk patients using a personalized, precision medicine prognostic assay to prevent progression to HGD/EAC.
This program is sponsored by Castle Biosciences.
Attention on MASH: Exploring the Role of Metabolic Dysfunction in a Chronic Liver Disease
Eric J. Lawitz, MD
2:45 pm – 3:15 pm
This presentation will review the underlying metabolic dysfunction in patients with MASH (metabolic dysfunction-associated steatohepatitis) and the impact of this dysfunction on disease progression. We will also review current AGA guidelines regarding patient identification, screening, and disease management.
This program is sponsored by Novo Nordisk.
